Table 1.
Baseline characteristics of the patients with HBV-associated ICC (n = 42)
| Variable | Patients (%) |
|---|---|
| Age | 54(35-77) |
| Gender | |
| Male | 28(66.7) |
| Female | 14(33.3) |
| HBsAg | 29(69.0) |
| HBcAb | 42(100) |
| AFP (μg/L) | 5.05(1.25-3000) |
| CA19-9(kU/L) | 47(10-8144) |
| Liver cirrhosis | 15(35.7) |
| Tumor size (cm) | 6.5(2.0-18.0) |
| Tumor number | |
| Single | 36(85.7) |
| Multiple | 6(14.3) |
| Resection type | |
| Minor hepatectomy | 20(47.6) |
| Major hepatectomy | 22(52.4) |
| APE status | |
| Positive | 15(35.7) |
| Negative | 9(21.4) |
| NA | 18(42.9) |
| Postoperative TACE | 9(21.4) |
| Histology | |
| Well or moderate | 17(40.5) |
| Poor | 25(59.5) |
| AJCC stage | |
| 1 | 16(38.1) |
| 2 | 6(14.3) |
| 3 | 5(11.9) |
| 4 | 15(35.7) |
| Vascular invasion | 16(38.1) |
| LNM | 15(35.7) |
HBsAg: hepatitis B surface antigen, HBcAb: hepatitis B core antibody, APE: arterial phase enhancement, NA: not applicable, TACE: transarterial chemoembolization, AJCC: American Joint Committee on Cancer, LNM: lymph node metastasis